Aristeia Capital’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-161,753
Closed -$1.36M – 892
2026
Q2
$1.36M Buy
+161,753
New +$1.35M 0.02% 299
2026
Q1
– Sell
-27,949
Closed -$345K – 728
2025
Q4
$345K Buy
+27,949
New +$299K 0.01% 373
2025
Q3
– Sell
-149,697
Closed -$955K – 561
2025
Q2
$955K Buy
+149,697
New +$857K 0.03% 168
2025
Q1
– Sell
-40,171
Closed -$384K – 456
2024
Q4
$384K Buy
+40,171
New +$369K 0.01% 219
2024
Q3
– Sell
-94,163
Closed -$642K – 399
2024
Q2
$642K Sell
94,163
-50,625
-35% -$218K 0.01% 121
2024
Q1
$366K Buy
+144,788
New +$326K 0.01% 133

Other funds holding EBS

Aristeia Capital's EBS Position: Q3 2026 in Review

Aristeia Capital sold out of Emergent Biosolutions (EBS) in Q3 2026, closing a stake of 161,753 shares — an estimated $1.36M sold.

Aristeia Capital first reported a position in EBS in Q1 2024 and held it in 6 quarters. The position peaked at $1.36M in Q2 2026. 183 funds tracked by Wall St. Rank hold EBS as of Q3 2026.

  • Aristeia Capital reported no remaining Emergent Biosolutions position as of Q3 2026 after selling out during the quarter.
  • Aristeia Capital sold 161,753 Emergent Biosolutions shares in Q3 2026, an estimated $1.36M.
  • Aristeia Capital first reported a position in Emergent Biosolutions in Q1 2024 and held it in 6 quarters.
  • Aristeia Capital's Emergent Biosolutions position peaked at $1.36M in Q2 2026.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2026.

Based on Aristeia Capital's 13F filing for Q3 2026, filed 16 Nov 2026.